Familial Mediterranean Fever (FMF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Familial Mediterranean Fever (FMF) Market Outlook

Thelansis’s “Familial Mediterranean Fever (FMF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Familial Mediterranean Fever treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Familial Mediterranean Fever Overview

Familial Mediterranean Fever (FMF) is an autoinflammatory genetic disorder characterized by recurring fevers and inflammation in the abdomen, lungs, and joints, causing severe pain. Symptoms may include a rash or headache. The onset of symptoms usually occurs in childhood and before the age of 20 years, with attacks manifesting within 2 to 4 hours and lasting 6 hours to 4 days. Mutations cause FMF in the MEFV gene on chromosome 16p13.3. Over 300 MEFV mutations have been identified, with 70 to 80% of cases attributed to V726A, M680I, E148Q, M694V, and M694I mutations. Pyrin plays a role in the pathophysiology of FMF, as it is found in the cytoskeleton of circulation cells, including white blood cells, which play a role in the immune response to pathogens. Mutations in the MEFV gene disrupt pyrin and its function, activating the inflammatory pathway through IL-1beta. Treatment for FMF involves using colchicine to prevent attacks, normalize inflammation, and prevent the development of amyloidosis. The prognosis of FMF depends on the frequency of attacks and the presence of complications, with improvement and decreased frequency of attacks typically seen with treatment. The presence of specific genotypes, such as M694V, increases the risk of complications such as renal amyloidosis and adverse prognosis. Secondary AA amyloidosis is a severe complication of FMF, with renal amyloidosis being the most common manifestation.

• In Spain, the prevalence of familial Mediterranean Fever is estimated to be less than 5 cases per 10,000 inhabitants.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: